```
=> d his l9-

     (FILE 'HCAPLUS' ENTERED AT 15:23:12 ON 25 MAR 1998)
                E PODOS S/AU
L9           91 S E4-E7
                E BECKER B/AU
L10         236 S E3-E11,E26-E28
                E MITTAG T/AU
L11          77 S E3-E9
L12         357 S L9-L11
L13          24 S L12 AND PROSTAGLAND?
L14           4 S L13 AND ?GLAUCOM?
L15          17 S L13 AND ?OCULAR?
L16           0 S L13 AND OPHTHALM?
L17       24625 S PGE1 OR PGE2
L18           8 S L17 AND L12
                SEL RN 1

     FILE 'REGISTRY' ENTERED AT 15:27:12 ON 25 MAR 1998
L19           5 S E1-E5
L20           2 S L19 AND C5/ES
                E 8-ISOPROSTAGLANDIN/CN
L21           2 S E4,E5

     FILE 'HCAPLUS' ENTERED AT 15:27:58 ON 25 MAR 1998
L22          56 S L21
L23          12 S 8()ISOPROSTAGLANDIN?()("E1" OR "E2")
L24           9 S 8()ISO()PROSTAGLANDIN?()("E1" OR "E2")
L25          25 S 8()ISO()(PGE1 OR PGE2)
L26          65 S L22-L25
L27           0 S L26 AND ?GLAUCOM?
L28           0 S L26 AND ?OCULAR?
L29           0 S L26 AND EYE
L30           0 S L26 AND EYEDROP
L31           1 S L26 AND L12
L32           5 S L26 AND 63/SC,SX
L33           2 S L26 AND 1/SC,SX
L34           1 S L21 (L) THU/RL
L35           7 S L32-L34 NOT L31

     FILE 'EMBASE' ENTERED AT 15:32:27 ON 25 MAR 1998
L36           6 S L21
                E 8 ISOPROSTAGLANDIN/CT
L37          16 S E4-E12
L38          16 S L36,L37
L39           0 S C2.290./CT AND L38
L40           0 S A9.70.10./CT AND L38
L41           0 S E8.540.800.925./CT AND L38

     FILE 'MEDLINE' ENTERED AT 15:36:48 ON 25 MAR 1998
L42           9 S L21
L43           0 S C11./CT AND L42
L44           0 S A9.371./CT AND L42

     FILE 'WPIDS' ENTERED AT 15:39:18 ON 25 MAR 1998
L45           1 S L23 OR L24 OR L25
L46           0 S 8()ISO()(PROSTAGLANDIN? OR PROSTA GLANDIN?)()("E1" OR "
```

=> fil reg

FILE 'REGISTRY' ENTERED AT 15:42:04 ON 25 MAR 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 22 MAR 98 HIGHEST RN 202973-59-9
DICTIONARY FILE UPDATES: 24 MAR 98 HIGHEST RN 202973-59-9

TSCA INFORMATION NOW CURRENT THROUGH JUNE 1997

Please note that search-term pricing does apply when conducting SmartSELECT searches.

=> d ide can tot l21

L21 ANSWER 1 OF 2 REGISTRY COPYRIGHT 1998 ACS
RN 27415-25-4 REGISTRY
CN Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,8.beta.,11.alpha.,13E,15S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-, stereoisomer (8CI)
OTHER NAMES:
CN 8-Iso-PGE2
CN **8-Isoprostaglandin E2**
FS STEREOSEARCH
MF C20 H32 O5
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CHEMCATS, CJACS, CSCHEM, EMBASE, MEDLINE, TOXLINE, TOXLIT
(*File contains numerically searchable property data)

Absolute stereochemistry.
Double bond geometry as shown.



33 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
33 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:132260

REFERENCE 2: 127:303605

REFERENCE 3: 127:289394

REFERENCE 4: 127:145532

REFERENCE 5: 127:76160

REFERENCE 6: 126:328929

REFERENCE 7: 126:328914

REFERENCE 8: 126:325925

REFERENCE 9: 126:113590

REFERENCE 10: 126:1302

L21 ANSWER 2 OF 2 REGISTRY COPYRIGHT 1998 ACS
RN 21003-46-3 REGISTRY
CN Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (8.beta.,11.alpha.,13E,15S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, stereoisomer (8CI)
OTHER NAMES:
CN 8-Iso-PGE1
CN 8-iso-PGE1
CN **8-Isoprostaglandin E1**
CN Isoprostaglandin E1
CN Ovinonic acid
FS STEREOSEARCH
DR 23756-23-2
MF C20 H34 O5
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CHEMCATS, CSCHEM, IFICDB, IFIPAT, IFIUDB, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.
Double bond geometry as shown.



30 REFERENCES IN FILE CA (1967 TO DATE)
30 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:132260

REFERENCE 2: 125:132161

REFERENCE 3: 112:1262

REFERENCE 4: 100:91466

REFERENCE 5: 99:169765

REFERENCE 6: 95:73964

REFERENCE 7: 94:58704

REFERENCE 8: 93:198219

REFERENCE 9: 93:25941

REFERENCE 10: 92:191674

=> fil wpids

FILE 'WPIDS' ENTERED AT 15:42:28 ON 25 MAR 1998
COPYRIGHT (C) 1998 DERWENT INFORMATION LTD

FILE LAST UPDATED: 23 MAR 1998 <19980323/UP>
>>>UPDATE WEEKS:
MOST RECENT DERWENT WEEK 199812 <199812/DW>
DERWENT WEEK FOR CHEMICAL CODING: 199807
DERWENT WEEK FOR POLYMER INDEXING: 199809
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> D COST AND SET NOTICE DO NOT REFLECT SUBSCRIBER DISCOUNTS - SEE HELP COST FOR DETAILS <<<
>>> CHANGES TO DWPI COVERAGE - SEE NEWS <<<

=> d bib abs l45

L45 ANSWER 1 OF 1 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
AN 72-06026T [04] WPIDS
TI Storage stable haemostatic transfusion suspensions of blood - platelets - contg glucose magnesium chloride and certain prostaglandin.
DC B04
PA (UPJO) UPJOHN CO
CYC 1
PI US 3629071 A (7204)*
PRAI US 70-10318 700210
AN 72-06026T [04] WPIDS
AB US 3629071 A UPAB: 930000
A storage-stable aqs. suspension in isotonic saline with effective complementary hemostatic activity preserving concns. of glucose and MgCl2 for translation comprises mammalian blood platelets and a prostoglandin chosen from PGE1; PGE1 is formate; **8-iso-PGE1**, dl-**8-iso PGE1**, methyl ester and 11-dehydro-PGF1 alpha the amount of prostoglandin being within the nontoxic effective range of 0.025 mu g/l- 1mg
ml. of the suspension. The suspension is sued in the treatment of idiopathic and drug related thrombocytopenias.

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 15:42:46 ON 25 MAR 1998

FILE COVERS 1967 - 25 Mar 1998 VOL 128 ISS 13
FILE LAST UPDATED: 25 Mar 1998 (980325/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file now supports REG1stRY for direct browsing and searching of all non-structural data from the REGISTRY file. Enter HELP FIRST for more information.

=> d bib abs hitrn tot l31

L31 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 1998 ACS
AN 1997:470682 HCAPLUS
DN 127:145532
TI Hemodynamic effects of isoprostanes (8-iso-prostaglandin F2.alpha. and E2) in isolated guinea pig hearts
AU Mobert, J.; **Becker, B. F.**; Zahler, S.; Gerlach, E.
CS Dep. of Physiol., Univ. of Munich, Munich, D-80336, Germany
SO J. Cardiovasc. Pharmacol. (1997), 29(6), 789-794
CODEN: JCPCDT; ISSN: 0160-2446
PB Lippincott-Raven
DT Journal
LA English
AB Isoprostanes are a family of prostaglandin-related compds. formed from arachidonic acid in a cyclooxygenase-independent manner as products of free radical-initiated lipid peroxidn. To elucidate the biol. activity of the F2- and E2-isoprostanes, 8-iso-prostaglandin F2.alpha. (8-iso-PGF2.alpha.) and **8-iso-prostaglandin E2** (**8-iso-PGE2**), the authors measured hemodynamic effects in isolated perfused guinea pig hearts after cumulative administration (3 .times. 10-9-10-5 M) of these compds. into the coronary system. Coronary flow (CF), left ventricular pressure (LVP), maximal rate of pressure development (dP/dtmax), and heart rate were detd. continuously. Furthermore, net release of lactate into the coronary venous effluent and myocardial pyruvate consumption were measured. Comparative studies were performed with the known potent vasoconstrictor endothelin-1 (6 .times. 10-12-2 .times. 10-9 M). Both 8-iso-PGF2.alpha. and **8-iso-PGE2** induced concn.-dependent decreases in CF, which declined maximally to .apprx.50% of the baseline level. The potencies of the two compds. were almost identical. Alterations in CF were assocd. in both groups with parallel redns. if LVP and dP/dtmax; heart rate was not influenced. Furthermore, the diminished CF caused enhanced lactate release and a reduced pyruvate consumption. All

isoprostane-induced hemodynamic changes were prevented by coapplication of the thromboxane A2-receptor antagonist SQ 29548 (1 .mu.M). Endothelin-1 caused CF redns. assocd. with loss of myocardial contractility, just like the isoprostanes. The authors conclude that in isolated guinea pig hearts, 8-iso-PGF2.alpha. and **8-iso-PGE2** are potent vasoconstrictors.
The action appears to be mediated by SQ 29548-responsive thromboxane receptors. The accompanying loss of contractility is a secondary phenomenon, elicited by infringed oxygen supply.

IT **27415-25-4, 8-Iso-prostaglandin E2**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(hemodynamic effects of isoprostanes in isolated guinea pig hearts)

=> d bib abs hitrn tot l35

L35 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1997:603881 HCAPLUS
DN 127:289394
TI The isoprostanes: unique bioactive products of lipid peroxidation
AU Morrow, Jason D.; Roberts, L. Jackson
CS Departments Medicine Pharmacology, Vanderbilt University School Medicine, Nashville, TN, 37232-6602, USA
SO Prog. Lipid Res. (1997), 36(1), 1-21
CODEN: PLIRDW; ISSN: 0163-7827
PB Elsevier
DT Journal; General Review
LA English
AB A review, with 94 refs. The discovery of IsoPs as products of non-enzymic lipid peroxidn. has opened up new areas of investigation regarding the role of free radicals in human physiol. and pathophysiol. The quantification of IsoPs as markers of oxidative stress status appears to be an important advance in our ability to explore the role of free radicals in the pathogenesis of human disease. A drawback related to this, however, has been lack of more facile and less expensive methods than mass spectrometry for the measurement of IsoPs. The recent introduction of immunoassay methods for measurement of IsoPs may alleviate this problem, provided they are specific and reliable. If this is the case, immunoassay methodol. will most likely lead to an expansion of the use of measurements of IsoPs to assess oxidative stress status in vivo. Another need in the field of free radical medicine is information regarding the clin. pharmacol. of antioxidant agents. Because of the evidence implicating free radicals in the pathogenesis of a no. of human diseases, large clin. trials are planned or underway to assess whether antioxidants can either prevent the development or ameliorate the pathol. of certain human disorders. However, data regarding the most EDs and combination of antioxidant agents to use in these clin. trials is lacking. As mentioned previously, administration of antioxidants suppresses the formation of IsoPs, even in normal individuals. Thus, measurement of IsoPs may provide a valuable approach to defining the clin. pharmacol. of antioxidants. In addn. to being markers of oxidative stress, at least two IsoPs possess potent biol. activity. The availability of addnl. IsoPs in synthetic form should broaden our

knowledge concerning the role of these mols. as mediators of oxidant stress. Moreover, information regarding the nature of the receptor(s) that mediate the biol. actions of IsoPs will be of considerable importance to the development of specific antagonists or agonists of the biol. actions of IsoPs. Despite the fact that considerable information has been obtained since the initial report of the discovery of IsoPs, much remains to be understood about these mols. With continued research in this area, we believe that much new information will emerge that will open up addnl. important new areas for future investigation.

IT **27415-25-4**, 8-IsoPGE2
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(lipid peroxidn. produces isoprostanes which are markers of oxidative stress and can assess the role of oxidant injury in human diseases)

L35 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1996:438517 HCAPLUS
DN 125:132161
TI Calcium antagonists attenuate isoprostane generation during oxidative modification of low density lipoprotein
AU Oguogho, Anthony; Leitinger, Norbert; Sinzinger, Helmut
CS Department Nuclear Medicine, University Vienna, Vienna, Austria
SO Niger. J. Physiol. Sci. (1995), 11(1 & 2), 29-31
CODEN: NPSCEA; ISSN: 0794-859X
DT Journal
LA English
AB F2-isoprostanes are non-enzymic chem.-stable end products of lipid peroxidn. In view of the reported biol. actions of isoprostanes and the proatherogenic potential of low-d. lipoprotein (LDL), we evaluated the efficiency of 10-3M and 10-5M of various calcium antagonists (nifedipine, amlodipine and diltiazem) to attenuate isoprostane generation in LDL (0.25 mg/mL) exposed to CuSO4 (5.mu.M). Attenuation of isoprostane generation in the presence of the tested calcium antagonists was evaluated after 90 min and 180 min of incubation. After 90 min of incubation there was a significant generation of isoprostanes in LDL exposed to copper only (360.+-.70) and this was significantly attenuated at 10-3M by nifedipine 58.37 .+-.10 > the novel compd. 71.12 .+-.24 > amlodipine 220 .+-.37 > diltiazem 465 .+-.33. As was obsd. at 10-3M, diltiazem showed no influence at 10-5M as well but there was a non-statistically significant attenuation by the novel compd. > amlodipine > nifedipine; however, after 180 min of incubation the novel compd. at 10-3M but not at 10-5M showed a significant attenuation while nifedipine and amlodipine lacked any influence. These results indicate that the formation of isoprostanes in LDL may contribute to the progression of atherosclerosis and their inhibition may account for the antiatherosclerotic action of calcium antagonists.

IT **21003-46-3, 8-Iso PGE1**
27415-25-4, 8-Iso PGE2
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(calcium antagonists attenuate isoprostane generation during oxidative modification of low d. lipoproteinin in relation to progression of atherosclerosis and its inhibition)

L35 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1985:529133 HCAPLUS
DN 103:129133
TI Stability indicating high performance liquid chromatographic procedure for the analysis of prostaglandin E2 raw material and tablets
AU Carignan, G.; Lodge, B. A.
CS Health Prot. Branch, Bur. Drug Res., Ottawa, ON, K1A 0L2, Can.
SO J. Liq. Chromatogr. (1985), 8(8), 1431-43
CODEN: JLCHD8; ISSN: 0148-3919
DT Journal
LA English
GI



I

AB A procedure is described for the quant. anal. of prostaglandin E2 (I) [363-24-6], its isomers, and degrdn. products. The HPLC method uses a CHCl3-hexane (70:30) mobile phase and a 250 .times. 4.6 mm, 5 .mu. cyano column, with testosterone as the internal std. The time required for chromatog. is approx. 15 min. The method gives a relative std. deviation of 1.7% for the assay of the drug in tablets.
IT **27415-25-4**
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, by HPLC in prostaglandin E2 stability studies)

L35 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1978:27742 HCAPLUS
DN 88:27742
TI Stability of prostaglandin E1 and dinoprostone (prostaglandin E2) under strongly acidic and basic conditions
AU Stehle, R. G.; Oesterling, T. O.
CS Pharm. Res., Upjohn Co., Kalamazoo, Mich., USA
SO J. Pharm. Sci. (1977), 66(11), 1590-5
CODEN: JPMSAE
DT Journal
LA English
GI



I



II

AB The stability of prostaglandin E1 (I) [745-65-3] and dinoprostone (II) [363-24-6] was investigated at the extremes of the pH range (.ltoreq.3 and .gtoreq.10) in the sequence prostaglandin E .fwdarw. prostaglandin A .fwdarw. prostaglandin B. The degrdn. rate is first order with hydrogen-ion and hydroxide-ion concns. Sepn. and anal. of the E prostaglandins were accomplished by TLC and UV spectrophotometry. At the lowest pH values and at elevated or low temps., significant amts. of 15-epiprostaglandin E were present. Apparent activation energies for the total II loss, calcd. from elevated temp. data, were 21 kcal/mol in the strongly acidic region and about 18 kcal/mol at pH 3. Corresponding studies in the alk. region led to a derived Arrhenius activation energy of 15 kcal/mol with the appearance of significant amts. of 8-isoprostaglandin E. This difference in activation energies may reflect the different mechanisms operant at high and low pH values.

IT **21003-46-3**
RL: BIOL (Biological study)
(prostaglandin E1 degrdn. product)

IT **27415-25-4**
RL: BIOL (Biological study)
(prostaglandin E2 degrdn. product)

L35 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1976:140764 HCAPLUS
DN 84:140764
TI Instant release of antiaggregation and nonthrombogenic agents to biological media
IN Ramwell, Peter W.; Shio, Hideo; Shaw, Jane E.
PA Alza Corp., USA
SO U.S., 9 pp.
CODEN: USXXAM
PI US 3932656 760113
AI US 70-71255 700910
DT Patent
LA English
GI



I

AB A polymeric material having a platelet aggregation inhibiting prostaglandin and possibly a nonthrombogenic agent incorporated on its surface for easy release when in close contact with blood, plasma, or platelets is reported. E.g., a 15 cm section of polyethylene [9002-88-4] catheter tubing was washed with EtOAc, rinsed with distd. water, and immersed in a 10% soln. of 11.alpha.,15.alpha.-dihydroxy-9-oxo-13-trans-prostenoic acid (I) [745-65-3] in EtOAc for 7-9 hr. The resultant tubing surface

released platelet aggregation inhibiting I.
IT **21003-46-3**
RL: BIOL (Biological study)
(on polymers, for platelet aggregation inhibition)

L35 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1973:435163 HCAPLUS
DN 79:35163
TI Novel device coated with a prostaglandin
IN Leeper, Harold M.; Ramwell, Peter W.
PA Alza Corp.
SO U.S., 8 pp.
CODEN: USXXAM
PI US 3730835 730501
AI US 71-134222 710415
DT Patent
LA English
AB A soln. of 1 g 11.alpha.,15(S)-dihydroxy-9-oxo-13-trans-prostenoic acid + 5 mg butylated hydroxytoluene in 20 ml EtOH was added to 15 g poly(vinylpyrrolidone) dissolved in 100 g EtOH at 50.degree.. A coiled Nichrome wire was dipped into this soln. and air dried. The cut up lengths could be inserted into blood collection tubes. Similar coatings were described for other prostaglandins and wire supports having large surface areas. These are for insertion into blood collection tubes or bags. The released prostaglandins prevents platelet aggregation.
IT **21003-46-3**
RL: BIOL (Biological study)
(wires coated with, for blood platelet aggregation prevention)

L35 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 1998 ACS
AN 1973:405046 HCAPLUS
DN 79:5046
TI Prostaglandins
IN Stadler, Istvan; Kovacs, Gabor; Meszaros, Zoltan; Radoczi, Julia; Simonidesz, Vilmos; Szantay, Csaba; Szekely, Istvan; Szakthmary, Csaba
PA Chinoin Gyogyszeres Vegyeszeti Termkek Gyara Rt.
SO Ger. Offen., 16 pp.
CODEN: GWXXBX
PI DE 2242792 730412
PRAI HU 71-CI1167 710928
DT Patent
LA German
GI For diagram(s), see printed CA Issue.
AB l- and(or) dl-Prostaglandin A1, B1, F1, E1 (I), E2 (II), and dl-**8-isoprostaglandin E1**, useful as arterial blood pressure lowering agents, child birth initiating agents, thromboses and stomach secretion inhibiting drugs, antilipolytics, and antiasthmatics, were prepd. by enzymic hydrolysis of the corresponding Me esters with lipase at pH 7.4. Thus, the ester l-III in H2O and EtOH was treated with lipase A during continuous 0.01 N NaOH addn. under N at pH 7.4 for 30 min at 25.degree. to give 92.5% l-I.

=> fil biosis

FILE 'BIOSIS' ENTERED AT 15:45:33 ON 25 MAR 1998

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 20 March 1998 (980320/ED)
CAS REGISTRY NUMBERS (R) LAST ADDED: 20 March 1998 (980320/UP)

=> d his l47-

(FILE 'REGISTRY' ENTERED AT 15:42:04 ON 25 MAR 1998)

FILE 'WPIDS' ENTERED AT 15:42:28 ON 25 MAR 1998

FILE 'HCAPLUS' ENTERED AT 15:42:46 ON 25 MAR 1998

FILE 'BIOSIS' ENTERED AT 15:43:57 ON 25 MAR 1998
L47 13 S L21
L48 1 S L47 AND AQUEOUS/TI
L49 1 S L47 AND (20006 OR 22031)/CC
L50 1 S L48,L49

FILE 'BIOSIS' ENTERED AT 15:45:33 ON 25 MAR 1998

=> d all

L50 ANSWER 1 OF 1 BIOSIS COPYRIGHT 1998 BIOSIS
AN 97:288797 BIOSIS
DN 99588000
TI Effect of 8-iso prostaglandin E-2 (8-iso PGE-2) on **aqueous** humor dynamics in monkeys.
AU Wang R-F; Lee P-Y; Mittag T; Podos S M; Serle J B; Becker B
CS Dep. Ophthalmol., Mount Sinai Sch. Med., New York, NY, USA
SO Annual Meeting of the Association for Research in Vision and Ophthalmology, Parts 1-2, Fort Lauderdale, Florida, USA, May 11-16, 1997. Investigative Ophthalmology & Visual Science 38 (4 PART 1-2). 1997. S815. ISSN: 0146-0404
DT Conference
LA English
PR Biological Abstracts/RRM Vol. 049 Iss. 007 Ref. 123606
ST MEETING ABSTRACT; MEETING POSTER; MONKEY; SENSE ORGANS; 8-ISO PROSTAGLANDIN E-2; AQUEOUS HUMOR DYNAMICS EFFECT; REDUCES INTRAOCULAR PRESSURE; EYE; GLAUCOMA; PHARMACOLOGY; SENSORY SYSTEM; EYE DISEASE
RN **27415-25-4** (8-ISO PGE-2)
CC General Biology-Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520
Biochemical Studies-General 10060
Sense Organs, Associated Structures and Functions-Pathology *20006
Pharmacology-Sense Organs, Associated Structures and Functions *22031
BC Primates-Unspecified 86190